1 WO 2 3 4 5 6 IN THE UNITED STATES DISTRICT COURT 7 FOR THE DISTRICT OF ARIZONA
9 Ronald L. Jackson, No. CV-18-02914-PHX-JJT
10 Plaintiff, ORDER
11 v.
12 Microchip Technology Incorporated, et al.,
13 Defendants. 14 15 At issue are Defendants Microchip Technology Inc., Steve Sanghi, Ganesh Moorthy 16 and J. Eric Bjornholt’s Motion to Dismiss Amended Complaint and Motion to Strike 17 (Doc. 36, Mot.), to which Plaintiff Ronald L. Jackson filed a Response (Doc. 39, Resp.) 18 and Defendants filed a Reply (Doc. 42). The Court finds these matters appropriate for 19 resolution without oral argument. See LRCiv 7.2(f). 20 I. BACKGROUND 21 In this federal securities fraud class action, the Court appointed Ronald L. Jackson, 22 Trustee Under Agreement Dated 01/05/2012 by Ronald L. Jackson, as Lead Plaintiff under 23 Section 21D(a)(3)(B) of the Securities Exchange Act of 1934 (“the Act”) as amended by 24 the Private Securities Litigation Reform Act of 1995 (“the PSLRA”), 15 U.S.C. § 78u- 25 4(a)(3)(B), after finding he was the most adequate plaintiff under the PSLRA based on his 26 monetary loss of $214,240 allegedly resulting from Defendants’ wrongful conduct. 27 (Doc. 24.) Defendant Microchip Technology Inc. (“Microchip”) is a publicly-traded 28 company headquartered in Arizona that manufactures computer chips, and Defendant 1 Steve Sanghi is its Chief Executive Officer and Chairman of the Board of Directors, 2 Defendant Ganesh Moorthy is its President and Chief Operating Officer, and Defendant J. 3 Eric Bjornholt is its Senior Vice President and Chief Financial Officer. 4 On March 1, 2018, Microchip announced its intent to acquire Microsemi Corp., 5 another chip manufacturer, for $10.15 billion financed by $8.6 billion in new debt, by way 6 of a press release issued to the public and filed with the Securities and Exchange 7 Commission (“SEC”). Also on March 1, 2018, Sanghi, Moorthy, and Bjornholt “conducted 8 Analyst Day via an in-person presentation and question and answer session with investors 9 and at least 14 stock research analysts,” which was “also broadcast via conference 10 call/webcast for those persons who were not invited to attend” and a transcript of which 11 was filed with the SEC. (Doc. 32, Am. Compl. ¶ 202.) Plaintiff alleges that “[i]nvestors 12 and stock-analysts expressed concern with the cost of the transaction and Microchip’s 13 ability to service the $8.6 billion in debt.” (Am. Compl. ¶ 3.) Microchip publicly discussed 14 the benefits of acquiring Microsemi through a May 8, 2018 press release and conference 15 call; a May 10, 2018 Moorthy presentation; and 2018 SEC Forms 10-K and 8-K. On 16 May 29, 2018, Microchip issued a press release announcing that the acquisition closed, and 17 Microchip continued to communicate with the public about the acquisition through a 18 May 31, 2018 press release and conference call; a June 4, 2018 Moorthy presentation; a 19 June 6, 2018 Bjornholt presentation; and a June 12, 2018 Moorthy presentation. Plaintiff 20 alleges that “Defendants repeatedly assured investors that although the cost of the 21 transaction was steep, the debt would be paid through free cash flow generated by the 22 combined entities after the Merger.” (Am. Compl. ¶ 3.) 23 In the Amended Complaint, the operative pleading, Plaintiff alleges that Defendants 24 made 52 materially false statements or omissions—which the Court will refer to with “FS” 25 throughout this Order—in their communications with the public related to Microchip’s 26 acquisition of Microsemi.1 At base, Plaintiff contends that Defendants knowingly 27 misrepresented the amount of inventory in Microsemi’s distribution channel and thus the
28 1 In fact, the Amended Complaint identifies 53 materially false statements or omissions, but Plaintiff later withdrew one (FS 47). (Resp. at 17 n.19.) 1 net free cash flow available to pay the substantial debt incurred in the acquisition. 2 Specifically, Plaintiff alleges that 3 Defendants misrepresented that the debt was only a 4.7 multiple of [Earnings Before Interest, Tax, Depreciation, and Amortization (“EBITDA”)] (a proxy 4 for cash flow) to be generated by the Merger. Defendants failed to disclose that the $8.6 billion in debt was a five times multiple of cash flow expected 5 to be generated by the Acquisition. The Transaction closed on May 29, 2018, and thereafter Microchip and Microsemi reported operations on a 6 consolidated basis. Actual cash flow generated by the Merger, beginning May 29, 2018, was approximately $110 million less than represented to 7 Microchip’s investors because of Microsemi’s higher inventory levels. These higher levels were caused, according to Microchip, because historically 8 toward the end of each quarter Microsemi had sold inventory to distributors and end users for cash at discounted prices in excess of their current needs. 9 10 (Am. Compl. ¶ 4.) 11 Defendants explain that, 12 [p]rior to 2018, semiconductor companies recognized revenue in different ways: (1) sales to distributors could be recognized upon shipment to the 13 distributor, also referred to as “sell-in”; or (2) sales to distributors could be recognized upon reported resale of the product by the distributors to their 14 customers, the ultimate end users, also referred to as “sell-through.” Historically, Microsemi reported its net sales on a “sell-in” basis, and 15 Microchip generally reported its net sales on a “sell-through” basis. Recent changes in revenue recognition reporting rules now provide for uniform 16 reporting of net sales on a “sell-in” basis. Following the changes in revenue recognition reporting rules, Microchip provides [Generally Accepted 17 Accounting Principles (“GAAP”)] sell-in net sales and also provides [non- GAAP] sell-through information. 18 19 (Mot. at 5.) 20 Plaintiff alleges that Microchip ultimately concluded that Microsemi could 21 constructively inflate its revenue numbers in a certain reporting period through a practice 22 of “stuffing” its distribution channel with sales to distributors in amounts above the 23 distributors’ current needs. (Am. Compl. ¶ 6.) According to Plaintiff, Defendants 24 conducted extensive pre-acquisition due diligence and knew about Microsemi’s inventory 25 practices before the acquisition but failed to disclose to investors and stock analysts that 26 Microsemi’s “historically reported GAAP revenue was not representative of true user 27 demand.” (Am. Compl. ¶ 6.) And Defendants knew but failed to disclose that Microsemi’s 28 high inventory levels would “result in lower sell-through (non-GAAP) revenue, lower free 1 cash flow, lower EBITDA, and a lower ability to delever the combined company through 2 paying down debt.” (Am. Compl. ¶ 10.) 3 Ultimately, “[o]n August 9, 2018, a little more than two months after the Merger 4 closed, Defendants announced the truth that Microsemi had four plus months of inventory 5 in Microsemi’s distribution channel and, as a result, Microchip had $110 million less of 6 net free cash flow and higher debt leverage (5.0 v. 4.7 times EBITDA).” (Am. Compl. 7 ¶ 15.) As a result, Microchip would be unable to pay down its debt rapidly, and “Microchip 8 common stock fell $10.67 a share, causing significant damages to members of the Class” 9 who had purchased stock between March 2 and August 9, 2018. (Am. Compl. ¶¶ 1, 17.) 10 Generally, Plaintiff’s allegations of Defendants’ false statements and omissions fall 11 into four substantive categories: (1) statements having to do with the strength of 12 Microsemi’s business and the compelling nature of the merger between Microchip and 13 Microsemi (Resp. at 4 (listing FS 18, 20–21, 24, 27, 29, 37 & 46; Am. Compl. ¶¶ 270, 278, 14 291, 307, 318, 330, 337 & 357)); (2) statements regarding Microsemi’s inventory and sales 15 practices (Resp. at 4–5 (listing FS 16–17, 32–33, 35–36, 51–52; Am. Compl. ¶¶ 213, 335– 16 36, 362–63)); (3) statements regarding Microsemi’s financial results (Resp. at 5 (listing FS 17 3–7, 9–15, 22–23, 25–26, 31, 50; Am. Compl. ¶¶ 206–09, 211–12, 292, 297, 309, 311, 334, 18 359)); and (4) statements regarding Microchip’s post-merger financial condition, debt 19 leverage, cash flow, and ability to reduce debt (Resp. at 5–6 (listing FS 1–2, 9–11, 19, 28, 20 30, 34, 38–49, 53; Am. Compl. ¶¶ 204, 211, 277, 329, 332, 335, 345–46, 352–54, 356–58, 21 367)).) 22 Plaintiff, on behalf of the putative class, filed this lawsuit on September 14, 2018, to 23 bring two claims against Defendants: (1) securities fraud liability under Section 10(b) of the 24 Act, 15 U.S.C. § 78j(b), and SEC Rule 10b-5, 17 C.F.R. § 240.10b-5; and (2) joint and 25 several liability of controlling persons under Section 20(a) of the Act, 15 U.S.C. § 78t(a). 26 Defendants now move to dismiss Plaintiff’s claims. 27 Separately, on October 9, 2018, four former Microsemi corporate officers filed a 28 complaint in California state court to raise claims of defamation, trade libel, and unfair 1 competition against Microchip and four of its corporate officers, including the three 2 individual Defendants in the present lawsuit. The basis of the plaintiffs’ claims is that certain 3 of the defendants’ post-merger statements harmed the plaintiffs’ professional reputations. 4 (Doc. 38-3 at 19–75, Peterson v. Sanghi, No. 18-cv-02000-JLS (C.D. Cal. Oct. 9, 2018) 5 (“Peterson Complaint”).) Certain of Plaintiff’s allegations in the Amended Complaint of this 6 lawsuit refer to allegations from the Peterson Complaint, which allegations Defendants ask 7 this Court to strike. 8 II. LEGAL STANDARDS 9 When analyzing a complaint for failure to state a claim for relief under Federal Rule 10 of Civil Procedure 12(b)(6), the well-pled factual allegations are taken as true and 11 construed in the light most favorable to the nonmoving party. Cousins v. Lockyer, 568 F.3d 12 1063, 1067 (9th Cir. 2009). Legal conclusions couched as factual allegations are not 13 entitled to the assumption of truth, Ashcroft v. Iqbal, 556 U.S. 662, 680 (2009), and 14 therefore are insufficient to defeat a motion to dismiss for failure to state a claim. In re 15 Cutera Sec. Litig., 610 F.3d 1103, 1108 (9th Cir. 2010). 16 A dismissal under Rule 12(b)(6) for failure to state a claim can be based on either (1) 17 the lack of a cognizable legal theory or (2) insufficient facts to support a cognizable legal 18 claim. Balistreri v. Pacifica Police Dep’t, 901 F.2d 696, 699 (9th Cir. 1990). “While a 19 complaint attacked by a Rule 12(b)(6) motion does not need detailed factual allegations, a 20 plaintiff’s obligation to provide the ‘grounds’ of his ‘entitle[ment] to relief’ requires more 21 than labels and conclusions, and a formulaic recitation of the elements of a cause of action 22 will not do.” Bell Atl. Corp. v. Twombly, 550 U.S. 544, 555 (2007) (citations omitted). The 23 complaint must thus contain “sufficient factual matter, accepted as true, to ‘state a claim to 24 relief that is plausible on its face.’” Iqbal, 556 U.S. at 678 (quoting Twombly, 550 U.S. at 25 570). “[A] well-pleaded complaint may proceed even if it strikes a savvy judge that actual 26 proof of those facts is improbable, and that ‘recovery is very remote and unlikely.’” 27 Twombly, 550 U.S. at 556 (quoting Scheuer v. Rhodes, 416 U.S. 232, 236 (1974)). 28 1 Where a plaintiff alleges fraud or misrepresentation, Federal Rule of Civil 2 Procedure 9(b) imposes heightened pleading requirements. While malice, intent, 3 knowledge, and other conditions of mind usually may be alleged generally, the 4 circumstances constituting fraud must be pled with particularity. Fed. R. Civ. P. 9(b). 5 Specifically, “[a]verments of fraud must be accompanied by ‘the who, what, when, where, 6 and how’ of the misconduct charged.” Vess v. Ciba-Geigy Corp. USA, 317 F.3d 1097, 1106 7 (9th Cir. 2003) (quoting Cooper v. Pickett, 137 F.3d 616, 627 (9th Cir. 1997)). 8 Furthermore, 9 a plaintiff must set forth more than the neutral facts necessary to identify the transaction. The plaintiff must set forth what is false or misleading about a 10 statement, and why it is false. In other words, the plaintiff must set forth an explanation as to why the statement or omission complained of was false or 11 misleading. 12 In re GlenFed, Inc. Sec. Litig., 42 F.3d 1541, 1548 (9th Cir. 1994). 13 The PSLRA, 15 U.S.C. § 78u-4, also imposes more exacting pleading standards in 14 private securities fraud lawsuits such as this one. With regard to alleged untrue statements or 15 omissions of material fact, “the complaint shall specify each statement alleged to have been 16 misleading, the reason or reasons why the statement is misleading, and, if an allegation 17 regarding the statement or omission is made on information and belief, the complaint shall 18 state with particularity all facts on which that belief is formed.” 15 U.S.C. § 78u-4(b)(1). 19 Moreover, under the PSLRA, where recovery depends “on proof that the defendant 20 acted with a particular state of mind, the complaint shall, with respect to each act or omission 21 alleged to violate this chapter, state with particularity facts giving rise to a strong inference 22 that the defendant acted with the required state of mind.” 15 U.S.C. § 78u-4(b)(2)(A). The 23 Supreme Court has stated that the “strong inference” standard for pleading “facts evidencing 24 scienter, i.e., the defendant’s intention to deceive, manipulate, or defraud,” is not satisfied 25 simply through “alleged facts from which, if true, a reasonable person could infer that the 26 defendant acted with the required intent.” Tellabs, Inc. v. Makor Issues & Rights, Ltd., 551 27 U.S. 308, 313–14 (2007) (internal quotations omitted). 28 Rather, to determine whether a complaint’s scienter allegations can survive threshold inspection for sufficiency, a court . . . must engage in a comparative 1 evaluation; it must consider, not only inferences urged by the plaintiff . . . , but also competing inferences rationally drawn from the facts alleged. An 2 inference of fraudulent intent may be plausible, yet less cogent than other, nonculpable explanations for the defendant’s conduct. To qualify as “strong” 3 within the intendment of [the PSLRA] . . . , an inference of scienter must be more than merely plausible or reasonable—it must be cogent and at least as 4 compelling as any opposing inference of nonfraudulent intent. 5 Id. at 314. 6 III. ANALYSIS 7 A securities fraud claim under § 10(b) and Rule 10b-5 requires that a plaintiff 8 demonstrate “(1) a material misrepresentation or omission; (2) scienter; (3) a connection 9 between the misrepresentation or omission and the purchase or sale of a security; (4) reliance; 10 (5) economic loss; and (6) loss causation.” Or. Pub. Emps. Ret. Fund v. Apollo Grp. Inc., 11 774 F.3d 598, 603 (9th Cir. 2014). “A defendant who makes misrepresentations or 12 omissions either intentionally or with deliberate recklessness acts with scienter.” Id. at 607 13 (internal quotations omitted). Thus, falsity allegations are evaluated “in light of specific 14 contemporaneous statements or conditions that demonstrate the intentional or the 15 deliberately reckless false or misleading nature of the statements when made.” Ranconi v. 16 Larkin, 253 F.3d 423, 432 (9th Cir. 2001) (internal quotations omitted). Defendants argue 17 that Plaintiff’s claim fails at elements (1) and (2) because Plaintiff fails to adequately plead 18 that Defendants made material false or misleading statements or omissions knowing they 19 were false or misleading and thus with the requisite intent or deliberate recklessness. The 20 Court will examine in turn Defendants’ arguments that Plaintiff fails to sufficiently allege 21 actionable misrepresentations and omissions. 22 A. The PSLRA Safe Harbor for Forward-Looking Statements 23 In the PSLRA, Congress created a “safe harbor” from liability for a person who 24 makes a “forward-looking statement,” as defined in the subsection, under certain 25 circumstances. 15 U.S.C. § 78u-5(c). Defendants contend that they are entitled to safe 26 harbor protection under the PSLRA for 33 of the alleged false or misleading statements. 27 (Mot. at 10–12 & n.3.) 28 1 Under the statute, forward-looking statements include statements expressing (A) “a 2 projection of revenues, income (including income loss), earnings (including earnings loss) 3 per share, capital expenditures, dividends, capital structure, or other financial items”; (B) 4 “the plans and objectives of management for future operations, including plans or 5 objectives relating to the products or services of the issuer [of securities]”; (C) “future 6 economic performance, including any such statement contained in a discussion and 7 analysis of financial condition by the management or in the results of operations”; and (D) 8 “the assumptions underlying or relating to any statement described in subparagraph (A), 9 (B), or (C).” 15 U.S.C. § 78u-5(i)(1). Fraud liability for making a forward-looking 10 statement cannot arise if the statement is (1) “identified as a forward-looking statement, 11 and is accompanied by meaningful cautionary statements identifying important factors that 12 could cause actual results to differ materially from those in the forward-looking statement”; 13 (2) “immaterial”; or (3) not made “with actual knowledge . . . that the statement was false 14 or misleading.” 15 U.S.C. § 78u-5(c)(1)–(2). Upon the filing of a motion to dismiss, the 15 Court “shall consider any statement cited in the complaint and any cautionary statement 16 accompanying the forward-looking statement, which are not subject to material dispute, 17 cited by the defendant.” 15 U.S.C. § 78u-5(e). “The PSLRA’s safe harbor is designed to 18 protect companies and their officials from suit when optimistic projections of growth in 19 revenues and earnings are not borne out by events.” In re Quality Sys. Inc. Sec. Litig., 865 20 F.3d 1130, 1142 (9th Cir. 2017). 21 A non-forward-looking statement may be embedded in a “mixed statement” that 22 also includes forward-looking content. Id. In that instance, a “misleading statement about 23 current or past facts” embedded in a mixed statement is not protected by the PSLRA’s safe 24 harbor. Id. But a challenged statement should be “examined as a whole,” and if that 25 examination reveals that the statement is essentially forward-looking, the statute’s safe 26 harbor provision applies to it. Id. at 1141 (citing Police Ret. Sys. of St. Louis v. Intuitive 27 Surgical, Inc., 759 F.3d 1051, 1059 (9th Cir. 2014)). 28 1 1. Statements about Stress-Testing Results and Merger Benefits 2 In response to Defendants’ argument that 33 of their statements were forward- 3 looking and protected by the PSLRA’s safe harbor, Plaintiff argues that four of these 4 statements concerned Microchip’s stress-testing of its acquisition of Microsemi, which 5 were “clearly not forward looking, in whole or in part.” (Resp. at 15 (listing FS 12–15; 6 Am. Compl. ¶ 212).) On the March 1, 2018 Analyst Day, “Sanghi responded to questions 7 regarding analysts[’] concerns of adding another $5 billion in debt by reassuring investors 8 that Microchip had ‘stress-tested’ Microchip’s ability to take on this debt, i.e. the free cash 9 flow that would be generated post-closing of the Transaction.” (FS 12; Am. Compl. ¶ 212; 10 see also FS 13–15.) Plaintiff argues this statement was misleading because Sanghi “failed 11 to disclose the known ‘stress’ factor that Microchip’s short-term cash flow would be 12 approximately $110 million less than represented because of excess inventory in the 13 channel.” (Resp. at 15.) 14 The Court agrees with Defendants (Reply at 5–6) that the essential nature of 15 Sanghi’s statements in FS 12–15 was forward-looking as contemplated by the PSLRA. 16 Even if the subject Sanghi discussed was the stress-testing Defendants had conducted— 17 which is ostensibly past or current information—the content had to do principally with 18 projections of future earnings and cash flow (and Microchip’s ability to delever quickly), 19 as well as certain assumptions underlying those projections in the form of hypothetical 20 future conditions, i.e., stress-testing. (See Am. Compl. ¶ 212.) The connection to 21 contemporaneous inventory data that Plaintiff argues can be inferred from Sanghi’s 22 statements is too attenuated to make any aspect of the statements non-forward-looking. 23 Compare In re Quality Sys., 865 F.3d at 1147 (noting that the defendants had made mixed 24 statements including specific statements that past and current sales were continually 25 growing when the data the defendants possessed allegedly showed declining sales). 26 The March 1, 2018 Analyst Day conference call also included a sufficiently 27 meaningful cautionary statement under the PSLRA. (Doc. 38-1 at 124.) As a result, FS 12– 28 15 are subject to the PSLRA safe harbor and not actionable here. 1 In a similar vein, Plaintiff argues that two of Defendants’ statements in the May 29 2 and May 31, 2018 press releases regarding the benefits of Microchip’s acquisition of 3 Microsemi are not forward-looking under the PSLRA. (Resp. at 15–16 (listing FS 27, 29; 4 Am. Compl. ¶¶ 318, 330).) There, Microchip gave projections of an enhanced product 5 portfolio, operational capabilities, customer base, and growth in earnings and value of the 6 company resulting from the Microsemi acquisition. These statements are again forward- 7 looking under the PSLRA; they did not include specific statements concealing Microsemi’s 8 alleged past or present inventory stuffing, as Plaintiff contends.2 Because the press releases 9 also included adequate, meaningful cautionary statements under the PSLRA (Doc. 38-1 at 10 399; Doc. 38-2 at 3–4), FS 27 and 29 are also subject to the safe harbor and not actionable. 11 2. Statements about the Debt Ratio 12 Plaintiff contends that eight of the 33 statements Defendants claim are safe-harbor 13 protected were essentially present statements about the Microsemi merger debt ratio and 14 thus not forward-looking. (Resp. at 16–17 (listing FS 1, 3, 30, 38, 42, 45, 48, 53; Am. 15 Compl. ¶¶ 204, 206, 332, 345, 352, 356, 358, 367).) As a representative example, Bjornholt 16 stated in the May 31, 2018 conference call that the “net leverage [total debt divided by 17 EBITDA] at the end of the June 2018 quarter is expected to be 4.7 times.” (FS 30; Am. 18 Compl. ¶ 30.) Plaintiff argues that, because the calculation depended on cash flow, which 19 Defendants already knew would be reduced in the upcoming quarters due to Microsemi’s 20 excess inventory in the channel, the statement was not forward-looking, but rather a mixed 21 statement of anticipated and existing fact and thus not entitled to safe harbor protection. 22 The Court again concludes that the statements Plaintiff challenges did not include 23 specific statements of past or present cash flow or inventory levels, which might make the 24 statements akin to the mixed statements in In re Quality Systems, 865 F.3d at 1147. Instead, 25 the statements fall quite squarely under the PSLRA’s safe harbor provision, because they 26 2 To the extent Plaintiff implies that Microchip’s statement “welcom[ing] Microsemi’s 27 employees into the Microchip family” was misleading because Microchip terminated the members of Microsemi’s senior management (Resp. at 15 (citing FS 27; Am. Compl. 28 ¶ 318)), Plaintiff neither adequately substantiates that argument nor explains why the alleged false statement is material. 1 are debt ratio projections for a future date based on certain cash flow assumptions. See 15 2 U.S.C. § 78u-5(i)(1). Because the statements also included adequate, meaningful 3 cautionary statements under the PSLRA (Doc. 38-1 at 124; Doc. 38-2 at 3–4, 22, 60, 96), 4 FS 1, 3, 30, 38, 42, 45, 48 and 53 are also subject to the safe harbor and not actionable. 5 3. Adequacy of Cautionary Statements 6 Plaintiff does not disagree with Defendants that the remaining 19 of 33 forward- 7 looking statements are indeed forward-looking. (Resp. at 17–18 (listing FS 2, 8–11, 16, 19, 8 21, 28, 31, 34, 39–41, 43–44, 47, 49, 51; Am. Compl. ¶¶ 205, 210–11, 213, 277, 291, 329, 9 334–35, 345–46, 353–54, 358, 362).)3 Instead, Plaintiff argues that the statements are not 10 entitled to safe harbor protection because they did not include meaningful cautionary 11 statements, namely, disclosure that Microsemi had excess inventory in the channel. (Resp. 12 at 17.) 13 Under the PSLRA, a meaningful cautionary statement must identify “important 14 factors that could cause actual results to differ materially from those in the forward-looking 15 statement.” 15 U.S.C. § 78u-5(c)(1)-(2). Defendants’ cautionary statements detailed 16 myriad important factors that could cause actual performance to differ from Defendants’ 17 projections, including such factors as “the mix of inventory we hold and our ability to 18 satisfy short-term orders from our inventory, . . . the levels of orders that are received and 19 can be shipped in a quarter, the level of sell-through of our products through distribution, 20 [and] changes or fluctuations in customer order patterns and seasonality.” (Doc. 38-1 at 21 124.) The cautionary statements also reference the companies’ SEC filings and websites, 22 among other resources, for a more detailed discussion of risk factors. (Doc. 38-1 at 124.) 23 The Court disagrees with Plaintiff that the cautionary statements had to include details 24 about Microsemi’s present inventory levels; indeed, this is simply another way of arguing 25 that the forward-looking statements—which Plaintiff concedes are forward-looking— 26 contained or had to contain past or present information. 27 28 3 The Court again notes that Plaintiff withdrew FS 47. 1 Accordingly, FS 2, 8–11, 16, 19, 21, 28, 31, 34, 39–41, 43–44, 49 and 51 are subject 2 to the safe harbor and not actionable. 3 B. The False or Misleading Nature of the Statements 4 Defendants contend that the remaining 20 alleged false or misleading statements 5 identified in the Amended Complaint are not accompanied by sufficient allegations to 6 demonstrate that the statements were false or misleading. (Mot. at 13 (listing FS 4–7, 18, 7 20, 22–23, 25, 50; Am. Compl. ¶¶ 207–09, 270, 278, 292, 297, 309, 359).) 8 To begin with, the Court agrees with Defendants (Mot. at 13 n.6 (listing FS 16, 17; 9 Am. Compl. ¶ 213)) that Plaintiff does not allege facts to show that statements regarding 10 Microchip’s pre-merger inventory level, in and of itself, were false or misleading. 11 Accordingly, FS 17 is not actionable.4 12 Likewise, Defendants’ statements of optimism in the corporate acquisition are not 13 actionable. (See Mot. at 16 (listing FS 8, 17, 27, 37, 46, 52; Am. Compl. ¶¶ 210, 213, 318, 14 337, 357, 363).) “Statements of mere corporate puffery, vague statements of optimism like 15 ‘good,’ ‘well-regarded,’ or other feel good monikers, are not actionable because 16 professional investors, and most amateur investors as well, know how to devalue the 17 optimism of corporate executives.” Intuitive Surgical, Inc., 759 F.3d at 1060 (quoting In re 18 Cutera Sec. Litig., 610 F.3d at 1111) (internal quotation marks omitted). Here, Defendants’ 19 statements that they are “pleased and proud to have closed this acquisition in a record time” 20 (FS 37; Am. Compl. ¶ 337), “the state of the union at Microchip is very, very strong” (FS 21 46; Am. Compl. ¶ 357), and Microsemi “is a much better run company” than a previously 22 acquired company (FS 52; Am. Compl. ¶ 363), are feel-good statements of optimism that 23 are not actionable as false or misleading statements.5 24 In the remaining 16 alleged false or misleading statements, Plaintiff’s theory of 25 liability reveals itself more directly. (See FS 4–7, 18, 20, 22–26, 32–33, 35–36, 50; Am. 26 Compl. ¶¶ 207–09, 270, 278, 292, 297, 307, 309, 311, 335–36, 359).) At base, Plaintiff 27 4 The Court already found that FS 16 is entitled to safe harbor protection under the PSLRA. 28 5 The Court already found that FS 8, 17, and 27 are not actionable for other reasons. 1 claims that Defendants knew (or were reckless in not knowing) that Microsemi’s 2 distribution channel was “stuffed” with excess inventory—a fact that was constructively 3 concealed by Microsemi’s practice of reporting revenue on a GAAP (or sell-in) basis— 4 and that many of Defendants’ statements regarding Microsemi’s inventory and revenue 5 were false or misleading in not disclosing the known or knowable practice of channel 6 stuffing. Defendants argue that Plaintiff’s allegations are not sufficient to demonstrate 7 Defendants’ statements were false or misleading because the statements simply had to do 8 with Microchip’s and Microsemi’s historical performance and were reported with 9 transparency—including acknowledging that Microsemi reported revenue on a GAAP (or 10 sell-in) basis—and express warnings of risk factors. (Mot. at 13–15, 17.) 11 The Court agrees with Defendants that some of the statements of historical 12 performance and Microchip’s plans for the merger were not misleading on their face, 13 though they do inform or give context to other, more questionable statements. In the May 14 8, 2018 press release, Microchip included a discussion of its practice of reporting revenue 15 on a non-GAAP (sell-through) basis and an update on the Microsemi acquisition, and 16 Plaintiff claims Defendants had a duty to also disclose Microsemi’s inventory practices 17 and current inventory levels together with the other statements. (See FS 18, 20; Am. Compl. 18 ¶¶ 270, 278.) The Act and Rule 10b-5 “prohibit only misleading and untrue statements, not 19 statements that are incomplete.” Brody v. Transitional Hosps. Corp., 280 F.3d 997, 1006 20 (9th Cir. 2002). To be misleading, an omission “must affirmatively create an impression of 21 a state of affairs that differs in a material way from the one that actually exists.” Id. Here, 22 Defendants’ omission of Microsemi’s alleged inventory levels did not make what 23 Defendants stated in the May 8, 2018 press release and associated conference call 24 misleading. The information given was of a general nature, and Defendants repeatedly 25 stated that Microsemi employed a GAAP (sell-in) basis to report revenue, in contrast to 26 Microchip’s practice of employing a non-GAAP (sell-through) basis. Similarly, 27 Microchip’s general statements in its SEC Form 10-K (FS 23; Am. Compl. ¶ 297) were not 28 misleading by omission. FS 18, 20 and 23 are thus not actionable in and of themselves. 1 But when Defendants’ statements regarding Microsemi’s historical performance 2 were more specific and tied to Microchip’s, Defendants plausibly created a false 3 impression. Although Defendants do not appear to have had historical revenue numbers 4 calculated on a non-GAAP (sell-through) basis for Microsemi, Sanghi reported 5 Microsemi’s historical revenue performance numbers on a non-GAAP basis on the March 6 1, 2018 Analyst Day conference call. (FS 4; Am. Compl. ¶ 207.) Indeed, on a slide entitled 7 “Highly Profitable Financial Model,” Sanghi reported Microchip’s non-GAAP-based 8 revenue next to Microsemi’s presumably GAAP-based revenue—calling all of the numbers 9 “non-GAAP”—and then added the two to present a total revenue number. (FS 6–7; Am. 10 Compl. ¶¶ 208–09.) 11 Defendants are correct that they were transparent in their communications by saying 12 that Microsemi employed a GAAP basis and Microchip employed a non-GAAP basis. But 13 it is a different matter to conflate the two, report apparently GAAP revenue numbers as 14 non-GAAP numbers, and ultimately to add numbers calculated on different bases to get a 15 sum non-GAAP revenue number. Considering the information Plaintiff alleges Defendants 16 had regarding Microsemi’s inventory-stuffed channel, the Financial Model—and 17 particularly the “Microchip + Microsemi” sum revenue number and the calculations 18 derived from it—was misleading. (See Am. Compl. ¶ 220 (“Defendants referenced and 19 discussed Microsemi’s reported GAAP net revenue without disclosing that the net revenue 20 numbers were inflated by Microsemi’s practice of stuffing the channel, and were not 21 representative of future anticipated revenue on a GAAP or non-GAAP basis.”) The Court 22 thus finds that Plaintiff has adequately alleged false or misleading statements in FS 4–7 23 (Am. Compl. ¶¶ 207–09)6 as well as in the instances Defendants later referred to the 24 Financial Model, namely, FS 22 (Am. Compl. ¶ 292 (Moorthy’s May 8, 2018 25 presentation)) and FS 50 (Am. Compl. ¶ 359 (Bjornholt’s June 6, 2018 presentation)). 26 In the same way, Plaintiff adequately alleges false or misleading statements in the 27 SEC Form 8-K. (FS 24–26; Am. Compl. ¶¶ 307, 309, 311.) There, Plaintiff alleges that 28 6 The Court reads these alleged statements and omissions together as a group. 1 “[t]he May 21, 2018 Form 8-K contained pro forma financial statements combining the 2 historical financial statements of Microchip and Microsemi,” yet the Form 8-K “failed to 3 disclose the known or knowable fact of what Microsemi’s non-GAAP net sales were,” and 4 if Defendants had disclosed the “true facts” regarding those numbers, “investors would 5 have learned that after [Microchip] adopted its same business practices for Microsemi’s 6 business,” Microsemi’s net sales and cash flow generation after the acquisition would be 7 materially below Microsemi’s prior quarters’ numbers. (Am. Compl. ¶¶ 311–13.) As thus 8 framed by Plaintiff, Defendants’ omission created an impression of a materially different 9 state of affairs than the one that actually existed. See Brody, 280 F.3d at 1006. Plaintiff has 10 thus sufficiently alleged false or misleading statements in FS 24, 25, and 26. 11 On May 31, 2018, two days after the acquisition closed, Microchip published a press 12 release and held a conference call. There, Sanghi reported that Microchip had “assessed 13 the non-GAAP revenue that Microsemi expected to ship in the quarter under our clock.” 14 (FS 32; Am. Compl. ¶ 335.) Sanghi stated that, going forward, “I think GAAP and non- 15 GAAP will be about the same because there would be just no incentive to put any more 16 parts into distribution than is required,” so revenue “would be in the similar range as we 17 have guided, $160 million to $18 million even if you look at by GAAP, give or take some.” 18 (FS 36; Am. Compl. ¶ 336.) Plaintiff claims that, because Sanghi was speaking directly 19 about Microsemi’s non-GAAP revenue, he misled investors by failing to disclose a fact 20 that Defendants knew or should have known: “Microsemi had pre-recognized non-GAAP 21 revenue in prior quarters through advance shipments.” (Am. Compl. ¶ 339.) Accordingly, 22 Defendants knew or should have known that their prior disclosure—upon which investors 23 and lending banks relied—that debt was a 4.7 times multiple of projected EBITDA was 24 untrue, and debt was actually five times EBITDA. (Am. Compl. ¶ 339.) Again, even taking 25 into account Defendants’ transparency as to Microsemi’s prior practice of reporting 26 revenue on a GAAP basis, Plaintiff has adequately alleged in FS 32, 33, 35 and 367 that 27 the omissions attendant to Defendants’ May 31, 2018 statements regarding Microsemi’s
28 7 The Court reads these alleged statements and omissions together as a group. 1 non-GAAP revenue were false or misleading. See In re Scientific-Atlanta, Inc. Sec. Litig., 2 239 F. Supp. 2d 1351, 1362–63 (N.D. Ga. 2002) (noting “a plaintiff may state a claim for 3 securities fraud by alleging that a company materially misrepresented its financial 4 condition by failing to disclose sales practices that encouraged customers to purchase 5 substantial advance inventories of product because such practices could reduce the 6 company’s future revenues”). 7 In sum, Plaintiff’s allegations are sufficient for the Court to plausibly infer that 8 Defendants made false or misleading statements in FS 4–7, 22, 24–26, 32–33, 35–36, and 9 50. 10 C. Scienter 11 With regard to the scienter element of Plaintiff’s securities fraud claim, it bears 12 repeating that a defendant acts with scienter if the defendant “makes misrepresentations or 13 omissions either intentionally or with deliberate recklessness.” Or. Pub. Emps. Ret. Fund, 14 774 F.3d at 607 (internal quotations omitted). Thus, falsity allegations are evaluated “in 15 light of specific contemporaneous statements or conditions that demonstrate the intentional 16 or the deliberately reckless false or misleading nature of the statements when made.” 17 Ranconi, F.3d at 432 (internal quotations omitted). Additionally, the Ninth Circuit has 18 stated: 19 Where, as here, the Plaintiffs seek to hold individuals and a company liable on a securities fraud theory, we require that the Plaintiffs allege scienter with 20 respect to each of the individual defendants. We may, however, impute scienter to individual defendants in some situations, for example, where we 21 find that a company’s public statements are so important and so dramatically false that they would create a strong inference that at least some corporate 22 officials knew of the falsity upon publication. 23 Or. Pub. Emps. Ret. Fund, 774 F.3d at 607–08 (internal quotations and citations omitted). 24 A portion of Plaintiff’s allegations concerning Defendants’ knowledge of their 25 statements’ false or misleading nature is derived from allegations by the plaintiffs—former 26 Microsemi corporate officers—in the Peterson Complaint. Plaintiff alleges that the 27 Peterson plaintiffs allege “that Microsemi provided all of its inventory, distribution, and 28 sales data to Microchip as part of the due diligence process,” and “Sanghi and others falsely 1 claimed that they only learned of those facts after the Acquisition closed.” (Am. Compl. 2 ¶ 72.) Moreover, Plaintiff alleges that Microsemi’s Executive Vice President, Frederick 3 Goerner, “gave a PowerPoint presentation to Sanghi and other Microchip executives that 4 detailed Microsemi’s relationships with its largest customers and the incentive programs 5 Microsemi had put in place to drive sales, showing the proportion of Microsemi’s revenue 6 that was attributable to sales to distributors.” (Am. Compl. ¶ 144.) 7 Defendants request that the Court strike those allegations as unreliable and unproven 8 because they are based on allegations in another lawsuit, relying on a footnote in an Order 9 from another case in this District, In re Apollo Grp., Inc. Sec. Litig., No. CV-10-1735- 10 PHX-JAT, 2011 WL 5101787, at *10 n.5 (D. Ariz. Oct. 27, 2011). (Mot. at 8–10.) But, as 11 Plaintiff points out, in that instance the first plaintiff relied on allegations from another 12 lawsuit in which the second plaintiffs had no first-hand knowledge of the facts underlying 13 their allegations. (Resp. at 7–8.) Here, by contrast, Plaintiff is referring to allegations of 14 facts the Peterson plaintiffs had first-hand knowledge of—facts related to actions they 15 themselves took or oversaw.8 For this reason, the Court declines to strike the challenged 16 allegations in this case.9 Those allegations can be considered in a holistic manner with 17 related allegations to determine the plausible inferences of scienter against which opposing 18 inferences must be weighed. See Zucco Partners, LLC v. Digimarc Corp., 552 F.3d 981, 19 1006 (9th Cir. 2009). 20 With regard to scienter, Plaintiff also includes the allegations of two Confidential 21 Witnesses (“CW1” and “CW2”)—two former Microsemi Sales Vice Presidents who 22 8 To the extent Defendants argue that some of Plaintiff’s allegations related to channel 23 stuffing in this lawsuit contradict those in the Peterson Complaint, whether channel stuffing occurred, to what extent, whether it was “improper,” and whether Defendants 24 believed it was improper are conclusions to be drawn by a fact-finder based on the sales and inventory information and other facts. That there are differences in the two Complaints 25 does not render the underlying facts related to Microsemi’s alleged presentation of its sales and inventory information to Microchip unreliable. 26 9 Relatedly, Federal Rule of Civil Procedure 11(b)(3) requires an attorney to make factual 27 allegations only if they “have evidentiary support or, if specifically so identified, will likely have evidentiary support after a reasonable opportunity for further investigation or 28 discovery.” That standard appears to have been met here, even if one attorney is in part relying on another. 1 allegedly gave Microsemi’s sales and inventory information to Microchip management 2 during the due diligence process. (Am. Compl. ¶¶ 157–72, 248–61.) Defendants argue 3 these allegations do not demonstrate Defendants’ knowledge of Microsemi’s sales and 4 inventory situation because the CWs were not Microchip employees, they never had 5 personal interactions with Sanghi and Bjornholt, and CW1 had only one 30-minute 6 interaction with Moorthy. However, the CWs do rely on first-hand knowledge, and Plaintiff 7 includes detailed factual allegations regarding the CWs’ interactions with Microchip 8 management. The allegations are thus sufficient for the Court to draw some inference of 9 scienter. 10 Plaintiff also alleges that, in a meeting with Microsemi employees on May 30, 2018, 11 Sanghi stated that, similar to Atmel—a company Microchip had acquired previously— 12 Microsemi’s poor sales incentive system “led to massive inventory stuffing through heavily 13 discounted sales, comparable to ‘two monkeys fighting and taking the price down.’” (Am. 14 Compl. ¶¶ 321–22.) In light of this admission that Sanghi was already of the opinion that 15 Microsemi had engaged in inventory stuffing, Plaintiff alleges that Sanghi’s statements to 16 investors on May 31, 2018, of post-acquisition inventory and revenue levels were 17 misrepresentations. 18 More generally, Plaintiff argues that Defendants’ actions in the Microsemi 19 acquisition must be viewed in the context of the collective experience and sophistication 20 of Sanghi, Bjornholt, and Moorthy, who had acquired 17 companies in the past. In addition, 21 Plaintiff points to allegations of Microchip’s “history of difficulties with acquired 22 companies’ inventory practices,” and specifically the fact that Microchip’s acquisition of 23 Atmel had resulted in the same inventory and revenue adjustments. (Resp. at 21–22.) 24 Likewise, Plaintiff contends that Defendants’ scienter must be evaluated in the context of 25 the fact that Microchip’s $10.15 billion acquisition of Microsemi was the largest in 26 Microchip’s history and financed with $8.6 billion in debt. In a situation in which the stakes 27 are so high, Plaintiff contends, it is difficult to conceive that Defendants’ due diligence 28 process did not reveal the inventory and revenue issues Defendants only announced on 1 August 9, 2018—over two months after the acquisition closed—and that at minimum a 2 failure to know and disclose such core information was deliberately reckless. 3 Of course, each side proffers different theories of Defendants’ motives. For their 4 part, Defendants argue that it would be counterintuitive for them to enter into an acquisition 5 that is “plagued with problems.” (Mot. at 23.) On the other hand, Plaintiff alleges among 6 other things that Defendants were motivated to make misleading statements regarding 7 revenue generation to obtain notes (issued in May 2018) at favorable rates, and that their 8 compensation regime valued revenue growth as a “significant factor.” (Am. Compl. ¶¶ 401, 9 458–75.) 10 Defendants contend that they were “continuing to gather information and learn 11 about Microsemi’s business through the class period,” and thus it is plausible they did not 12 know of Microsemi’s inventory and revenue practices until just before their announcement 13 on August 9, 2018. (Mot. at 10.) However, taking Plaintiff’s allegations of scienter as a 14 whole, the Court finds the inference that the individual Defendants knew of Microsemi’s 15 inventory and revenue practices and yet misrepresented or omitted key information in 16 communications with investors and stock analysts is cogent and at least as compelling as 17 any nonculpable inference proffered by Defendants. 18 Under the principles of respondeat superior, a plaintiff may establish scienter of the 19 corporation through the scienter of its corporate officers or directors. In re Hienergy Techs., 20 Inc. Sec. Litig., 2005 WL 3071250, at *8 (C.D. Cal. Oct. 25, 2005). Here, Plaintiff’s 21 allegations are sufficient for the Court to find that Microchip had constructive knowledge 22 of the facts known by the individual Defendants and other corporate officers. According to 23 Plaintiff’s allegations, Microsemi gave detailed information about its inventory and 24 revenue practices to Microchip’s corporate officers during the due diligence process but 25 the individual Defendants—either intentionally or with deliberate recklessness— 26 misrepresented or omitted core information in its public communications on behalf of 27 Microchip. Plaintiff has thus adequately alleged corporate scienter. 28 1 D. Other Matters 2 Defendants’ only basis for asking the Court to dismiss Count 2, for joint and several || liability of controlling persons under Section 20(a) of the Act, 15 U.S.C. § 78t(a), is that 4|| Plaintiff failed to state a claim for Count 1. Because the Court disagrees, Count 2 will proceed 5 || along with Count 1. 6 In the Response (Resp. at 25), Plaintiff asks the Court to deny Defendants’ request 7\| for the Court to take judicial notice of Defendants’ Exhibits 1, 2, 18, 19, and 20. Because 8 || the Court did not rely on any of those Exhibits to resolve Defendants’ Motion, the Court 9|| will deny Plaintiff's request as moot. 10 IT IS THEREFORE ORDERED granting in part and denying in part Defendants’ 11 || Motion to Dismiss Amended Complaint and Motion to Strike (Doc. 36). Plaintiff has stated || claims with regard to False Statements 4-7, 22, 24—26, 32-33, 35-36, and 50. The Court 13 || grants Defendants’ Motion to Dismiss with regard to the balance of the alleged False Statements. 15 IT IS FURTHER ORDERED denying Defendants’ request to strike certain allegations from the Amended Complaint. (Doc. 36.) 17 Dated this 11th day of March, 2020. CN iy. Unig States#District Judge 20 21 22 23 24 25 26 27 28
-20 -